20:58:25 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Bokslutskommuniké 2024
2024-04-19 Kvartalsrapport 2024-Q3
2024-04-12 Extra Bolagsstämma 2024
2024-02-09 Kvartalsrapport 2024-Q2
2023-10-27 Kvartalsrapport 2024-Q1
2023-09-25 Ordinarie utdelning VSD B 0.00 SEK
2023-09-22 Årsstämma 2024
2023-08-31 Bokslutskommuniké 2023
2023-05-04 Kvartalsrapport 2023-Q3
2023-02-09 Kvartalsrapport 2023-Q2
2022-10-27 Kvartalsrapport 2023-Q1
2022-10-07 Ordinarie utdelning VSD B 0.00 SEK
2022-10-06 Årsstämma 2023
2022-08-30 Bokslutskommuniké 2022
2022-07-05 Extra Bolagsstämma 2022
2022-05-04 Kvartalsrapport 2022-Q3
2022-02-11 Kvartalsrapport 2022-Q2
2021-10-22 Kvartalsrapport 2022-Q1
2021-10-06 Ordinarie utdelning VSD B 0.00 SEK
2021-10-05 Årsstämma 2022
2021-08-30 Bokslutskommuniké 2021
2021-05-12 Kvartalsrapport 2021-Q3
2021-02-12 Kvartalsrapport 2021-Q2
2020-11-12 Kvartalsrapport 2021-Q1
2020-10-08 Ordinarie utdelning VSD B 0.00 SEK
2020-10-07 Årsstämma 2021
2020-08-31 Bokslutskommuniké 2020
2020-05-15 Kvartalsrapport 2020-Q3
2020-05-04 Extra Bolagsstämma 2020
2020-02-14 Kvartalsrapport 2020-Q2
2019-11-01 Kvartalsrapport 2020-Q1
2019-10-10 Ordinarie utdelning VSD B 0.00 SEK
2019-10-09 Årsstämma 2020
2019-08-30 Bokslutskommuniké 2019
2019-05-16 Kvartalsrapport 2019-Q3
2019-02-14 Kvartalsrapport 2019-Q2
2018-10-30 Kvartalsrapport 2019-Q1
2018-10-17 Ordinarie utdelning VSD B 0.00 SEK
2018-10-16 Årsstämma 2019
2018-08-31 Bokslutskommuniké 2018
2018-05-16 Kvartalsrapport 2018-Q3
2018-02-14 Kvartalsrapport 2018-Q2
2017-10-30 Kvartalsrapport 2018-Q1
2017-10-02 Ordinarie utdelning VSD B 0.00 SEK
2017-09-29 Årsstämma 2018
2017-08-30 Bokslutskommuniké 2017
2017-05-22 Kvartalsrapport 2017-Q3
2017-02-20 Kvartalsrapport 2017-Q2
2017-01-25 Extra Bolagsstämma 2017
2016-11-07 Kvartalsrapport 2017-Q1
2016-08-29 Ordinarie utdelning VSD B 0.00 SEK
2016-08-26 Bokslutskommuniké 2016
2016-05-26 Kvartalsrapport 2016-Q3
2016-02-25 Kvartalsrapport 2016-Q2
2015-11-26 Kvartalsrapport 2016-Q1
2015-08-27 Bokslutskommuniké 2015

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Vibrosense Dynamics är verksamt inom medicinteknik. Bolaget utvecklar produkter och tjänster för diagnostikstöd vid nervskador i händer och fötter. Produkterna mäter och kvantifierar förmågan att känna vibrationer i huden, och används av vårdgivare för att kunna anpassa behandlingen eller sätta in förebyggande åtgärder vid potentiella nervskador. Bolagets kunder består huvudsakligen av diabetesmottagningar, sjukhus, vårdcentraler och forskningsinstitut.
2023-11-09 13:56:39

VibroSense Meter® II is now registered in Great Britain, which opens up a new market for the company's product. The VibroSense Meter® II facilitates reliable detection and diagnosis of peripheral nerve damage in hands and feet caused by, for example, diabetes, chemotherapy and hand-held vibrating tools.

All medical devices sold in the UK must be registered with the government agency "Medicines and Healthcare products Regulatory Agency" (MHRA). VibroSense Meter® II is now registered and shortly the product will be listed in the MHRA Public database https://pard.m  (https://pard.mhra.gov.uk/)h  (https://pard.mhra.gov.uk/)ra.gov.uk/ (https://pard.mhra.gov.uk/)

In July 2023, a change was introduced in the regulations which means that all CE-marked products according to the MDR can be sold in the UK up to and including 2028, provided that the product is registered with the MHRA.

"The registration of the VibroSense Meter® II means that we can now also sell Diabetic Foot Screening in the UK, which will be a further step forward in our international launch. As we have also received several requests from the UK, it is very gratifying that we can now deliver our product directly to the end customer in a very exciting and large market", says Hans Wallin, CEO of VibroSense Dynamics AB.

Contact
Hans Wallin, CEO VibroSense Dynamics AB
Tel: +46 40 88 026
Email: info@vibrosense.com
www.vibrosense.com (http://www.vibrosense.se/)

"The new Gold Standard for reliable
detection of nerve damage"

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical technology products and services for diagnostic support for nerve damage in the hands and feet caused by, for example, diabetes, chemotherapy or vibrating hand-held tools. The method involves measuring and quantifying the ability to feel vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers.

Our vision is that the company's products should be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.

About the Medicines and Healthcare products Regulatory Agency (MHRA)
The MHRA regulates medicines, medical devices and blood components for transfusion in the UK. The authority operates within a statutory framework set by HM Government , working within government and the wider health system to guide overall policy within a regulatory framework.

These policies set out the role to ensure improvements in public health and provide powers to deliver against their corporate responsibilities.